Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia

Blood

Volumn 109, Issue 5, 2007, Pages 2256-2262

  Wagner, John E ^a,g   Eapen, Mary ^b   MacMillan, Margaret L ^a   Harris, Richard E ^c   Pasquini, Ricardo ^d   Boulad, Farid ^e   Zhang, Mei Jie ^b   Auerbach, Arleen D ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

^g Mayo Mail Code 98   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CONVALESCENCE; CYTOMEGALOVIRUS; FANCONI ANEMIA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MORTALITY; NEUTROPHIL COUNT; ORGAN DONOR; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RISK FACTOR; SCHOOL CHILD; SEROLOGY; SURVIVAL; T CELL DEPLETION; THROMBOCYTE COUNT;

EID: 33847349880     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-036657     Document Type: Article

References (33)

1. Alter B, Young N. The bone marrow failure syndromes. In: Nathan DG, Orkin SH, eds. Hematology of Infancy and Childhood. 4th ed. Philadelphia, PA: W.B. Saunders; 1998:237-335.
2. Wagner JE, MacMillan ML, Auerbach AD. Hematopoietic cell transplantation for Fanconi anemia. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' Hematopoietic Cell Transplantation. Oxford, United Kingdom: Blackwell Publishing Ltd; 2003:1483-1506.
3. Auerbach AD, Joenje H, Buchwald M. Fanconi anemia. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. 2nd ed. New York, NY: McGraw-Hill; 2002:289-306.
4. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101:1249-1256.
5. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood. 1994;84:1650-1655.
6. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101:822-826.
7. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg. 2003;129:106-112.
8. Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood. 2000;95:422-429.
9. Boulad F, Gillio A, Small TN, et al. Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. Br J Haematol. 2000;111:1153-1157.
10. MacMillan ML, Wagner JE. Hematopoietic cell transplantation for congenital bone marrow failure. Curr Opin Oncol. 2005;17:106-113.
11. Farag S, Bacigalupo A, Eapen M, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12:876-884.
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
13. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am. 1999;13:1091-1112.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
15. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag; 2003.
16. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-200.
17. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood. 1995;86:2856-2862.
18. Davies SM, Khan S, Wagner JE, et al. Unrelated donor bone marrow transplantation for Fanconi anemia. Bone Marrow Transplant. 1996;17:43-47.
19. Wagner JE, Auerbach AD, Gandham S, et al. Unrelated donor hematopoietic cell transplantation (UD-HCT) for Fanconi Anemia (FA): impact of patient age, pretransplant performance status, prior androgens and fludarabine based conditioning on survival [abstract]. Blood. 2001;98:814a. Abstract 3384.
20. Berger R, Bernheim A, Gluckman E, Gisselbrecht C. In vitro effect of cyclophosphamide metabolites on chromosomes of Fanconi anaemia patients. Br J Haematol. 1980;45:565-568.
21. Auerbach AD, Adler B, O'Reilly RJ, Kirkpatrick D, Chaganti RS. Effect of procarbazine and cyclophosphamide on chromosome breakage in Fanconi anemia cells: relevance to bone marrow transplantation. Cancer Genet Cytogenet. 1983;9:25-36.
22. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol. 1983;54:431-440.
23. Gluckman E. Bone marrow transplantation in Fanconi's anemia. Stem Cells. 1993;11:180-183.
24. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997;5:137-148.
25. Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98:2532-2537.
26. Gross M, Hanenberg H, Lobitz S, et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res. 2002;98:126-135.
27. Drobyski WR. Evolving strategies to address adverse transplant outcomes associated with T cell depletion. J Hematother Stem Cell Res. 2000;9:327-337.
28. Rosenberg PS, Socie G, Alter BP, Gluckman E. Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants. Blood. 2005;105:67-73.
29. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
30. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell depletion trial): a multi-centre, randomised phase II-III trial. Lancet. 2005;366:733-741.
31. Drobyski WR, Klein J, Flomenberg N, et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood. 2002;99:806-814.
32. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience. Blood. 2001;98:2922-2929.
33. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339:1177-1185.